NASDAQ:ALT - Altimmune Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.29
  • Forecasted Upside: 443.09 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$4.84
▼ -0.45 (-8.51%)

This chart shows the closing price for ALT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Altimmune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALT

Analyst Price Target is $26.29
▲ +443.09% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $26.29, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 443.09% upside from the last price of $4.84.

This chart shows the closing price for ALT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Altimmune. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Piper SandlerLower Price TargetOverweight$34.00 ➝ $25.00High
5/17/2022HC WainwrightReiterated RatingBuy$25.00High
5/16/2022GuggenheimLower Price TargetNA$27.00High
3/22/2022HC WainwrightReiterated RatingBuy$25.00Medium
3/16/2022GuggenheimLower Price Target$33.00 ➝ $28.00High
1/24/2022B. RileyLower Price Target$27.00 ➝ $21.00High
12/30/2021Jefferies Financial GroupInitiated CoverageBuy$30.00Medium
9/28/2021JMP SecuritiesReiterated RatingBuy$31.00High
9/8/2021Piper SandlerBoost Price TargetOverweight$16.00 ➝ $34.00Low
9/7/2021B. RileyBoost Price TargetBuy$21.00 ➝ $27.00Low
8/30/2021HC WainwrightReiterated RatingBuy$25.00Medium
8/12/2021Jefferies Financial GroupBoost Price TargetIn-Line ➝ Buy$14.00 ➝ $30.00High
7/1/2021Evercore ISIReiterated RatingBuy$25.00Medium
6/30/2021B. RileyLower Price TargetBuy$41.00 ➝ $21.00High
6/30/2021GuggenheimLower Price TargetBuy$52.00 ➝ $42.00High
6/30/2021HC WainwrightLower Price TargetBuy$35.00 ➝ $25.00High
6/30/2021JMP SecuritiesLower Price TargetOutperform$53.00 ➝ $31.00High
6/16/2021JMP SecuritiesBoost Price TargetMarket Outperform$45.00 ➝ $53.00High
6/16/2021HC WainwrightReiterated RatingBuy$35.00High
6/2/2021HC WainwrightInitiated CoverageBuy$35.00Medium
2/18/2021B. RileyBoost Price TargetBuy$28.00 ➝ $41.00Low
2/10/2021GuggenheimInitiated CoverageBuy$36.00 ➝ $36.00Low
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$25.00High
11/24/2020Evercore ISIReiterated RatingOutperform$25.00N/A
11/12/2020B. RileyLower Price TargetBuy$31.00 ➝ $28.00High
10/13/2020B. RileyReiterated RatingBuy$31.00N/A
9/25/2020B. RileyInitiated CoverageBuy$31.00High
9/24/2020B. RileyReiterated RatingBuyHigh
8/14/2020Evercore ISIInitiated CoverageOutperformN/A
7/30/2020Piper SandlerInitiated CoverageOverweightN/A
7/28/2020JMP SecuritiesInitiated CoverageOutperformN/A
2/24/2020Roth CapitalInitiated CoverageBuy$13.00Low
7/19/2019Roth CapitalReiterated RatingBuyMedium
7/19/2019Roth CapitalInitiated CoverageBuy ➝ Buy$8.30N/A
5/29/2018Dawson JamesReiterated RatingBuyHigh
10/9/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$180.00N/A
(Data available from 5/19/2017 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 16 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/20/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/18/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
5/19/2022

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Altimmune logo
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $4.84
Low: $4.80
High: $5.35

50 Day Range

MA: $5.51
Low: $3.94
High: $7.21

52 Week Range

Now: $4.84
Low: $3.83
High: $19.46

Volume

540,748 shs

Average Volume

801,952 shs

Market Capitalization

$209.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Altimmune?

The following Wall Street research analysts have issued reports on Altimmune in the last year: B. Riley, Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ALT.

What is the current price target for Altimmune?

0 Wall Street analysts have set twelve-month price targets for Altimmune in the last year. Their average twelve-month price target is $26.29, suggesting a possible upside of 443.1%.
View the latest price targets for ALT.

What is the current consensus analyst rating for Altimmune?

Altimmune currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALT will outperform the market and that investors should add to their positions of Altimmune.
View the latest ratings for ALT.

How do I contact Altimmune's investor relations team?

Altimmune's physical mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The company's listed phone number is (240) 654-1450 and its investor relations email address is [email protected] The official website for Altimmune is altimmune.com. Learn More about contacing Altimmune investor relations.